{"id":34651,"date":"2024-11-26T17:06:14","date_gmt":"2024-11-26T17:06:14","guid":{"rendered":"https:\/\/bnssghealthiertogether.org.uk\/?page_id=34651"},"modified":"2024-11-26T17:06:14","modified_gmt":"2024-11-26T17:06:14","slug":"how-can-we-optimise-the-management-of-patients-with-inflammatory-bowel-disease","status":"publish","type":"page","link":"https:\/\/bnssghealthiertogether.org.uk\/ro\/integrated-care-board\/research-and-evidence\/our-research-portfolio\/type-2-rcf-funded-projects\/how-can-we-optimise-the-management-of-patients-with-inflammatory-bowel-disease\/","title":{"rendered":"Cum putem optimiza gestionarea pacien\u021bilor cu boli inflamatorii intestinale?"},"content":{"rendered":"<div class=\"assembler_default-group assembler_module_group assembler_default-group_1 assembler_module_group_1\"><div class=\"assembler_module_area assembler_module_area_1\"><div class=\"assembler_text-module assembler_module assembler_text-module_1 assembler_module_1  transparent\"><a tabindex=\"-1\" title=\"Sec\u021biunea intitulat\u0103 modul-1\" id=\"module-1\" href=\"https:\/\/bnssghealthiertogether.org.uk\/ro\/wp-json\/wp\/v2\/pages\/34651\/#module-1\" class=\"anchor\"><span class=\"hidden\">Sec\u021biunea intitulat\u0103 modul-1<\/span><\/a><!-- Template found for text-module - Template: template-text - Matched: _only --><section class=\"w-full mx-auto max-w-content pt-12 sm:pt-24 pb-12 sm:pb-24\">\r\n  <div class=\"entry-content w-full !px-0 max-w-small\">\r\n        <h1>Cum putem optimiza gestionarea pacien\u021bilor cu boli inflamatorii intestinale?<\/h1>\n<h2>Care este \u00eentrebarea de cercetare propus\u0103?<\/h2>\n<p>Cum putem optimiza gestionarea pacien\u021bilor cu boli inflamatorii intestinale?<\/p>\n<h2>Finan\u021bare<\/h2>\n<p>Finan\u021barea capacit\u0103\u021bii de cercetare BNSSG ICB.<\/p>\n<h2>Care este problema?<\/h2>\n<p>Boala inflamatorie intestinal\u0103 (BII), boala Crohn (BC) \u0219i colita ulceroas\u0103 (CU) sunt afec\u021biuni inflamatorii cronice ale intestinului care afecteaz\u0103 500.000 (1:123) de persoane \u00een Regatul Unit. BII este o afec\u021biune pe tot parcursul vie\u021bii, diagnosticat\u0103 de obicei la tineri cu v\u00e2rste cuprinse \u00eentre 10 \u0219i 30 de ani, care provoac\u0103 dizabilit\u0103\u021bi semnificative \u0219i adesea restric\u021bioneaz\u0103 capacitatea de a lucra normal.<\/p>\n<p>Tratamentul medical al bolilor inflamatorii intestinale (BII) a fost revolu\u021bionat acum aproximativ 30 de ani odat\u0103 cu introducerea primei terapii biologice, infliximab. De atunci, au fost dezvoltate mai multe terapii biologice \u0219i cu molecule mici pentru utilizarea \u00een BII.<\/p>\n<p>Cre\u0219terea num\u0103rului de op\u021biuni nu a fost \u00eenso\u021bit\u0103 de literatura de specialitate care s\u0103 \u00eei \u00eendrume pe medici cu privire la medicamentele pe care ar trebui s\u0103 le utilizeze mai \u00eent\u00e2i \u0219i cum s\u0103 le utilizeze mai departe \u00een cazul e\u0219ecului tratamentului. Datele preliminare par s\u0103 sugereze c\u0103 exist\u0103 o varia\u021bie semnificativ\u0103 \u00een practicile de prescriere, iar literatura actual\u0103 nu ne permite s\u0103 optimiz\u0103m rezultatul prin utilizarea resurselor. Acest lucru \u00eent\u00e2rzie remisia pentru pacien\u021bi \u0219i irose\u0219te resurse semnificative.<\/p>\n<h2>Care este scopul cercet\u0103rii?<\/h2>\n<p>Dezvoltarea unei c\u0103i pentru prioritizarea terapiei biologice \u0219i cu molecule mici pentru gestionarea bolilor inflamatorii intestinale, bazat\u0103 pe eficacitatea clinic\u0103, rentabilitatea \u0219i experien\u021ba pacientului.<\/p>\n<h2>Cum se va realiza acest lucru?<\/h2>\n<p>Mai \u00eent\u00e2i, vom descrie \u00eengrijirea pacien\u021bilor cu boli inflamatorii intestinale \u00een cadrul BNSSG, concentr\u00e2ndu-ne pe prescrierea local\u0103 \u0219i varia\u021bia \u00een func\u021bie de zon\u0103 \u0219i demografia pacien\u021bilor.<\/p>\n<p>\u00cen al doilea r\u00e2nd, vom colecta date despre rezultatele clinice, cum ar fi markerii sanguini \u0219i ai scaunului, pentru a identifica inflama\u021bia, precum \u0219i evenimentele adverse, cum ar fi intern\u0103rile \u00een spital, cure de steroizi \u0219i interven\u021biile chirurgicale. Acestea vor fi utilizate pentru a compara strategiile de tratament, oferind date din lumea real\u0103 pentru a completa ceea ce se \u0219tie despre eficacitatea clinic\u0103 a acestor medicamente \u00een cadrul studiului clinic.<\/p>\n<p>\u00cen al treilea r\u00e2nd, rentabilitatea poate fi evaluat\u0103 prin calcularea unui \u2018cost per remisie\u2019. Pentru un context suplimentar, vom include costul contactelor clinice de urgen\u021b\u0103 ulterioare pentru terapiile e\u0219uate \u0219i rezultatele clinice adverse ale fiec\u0103rui tratament.<\/p>\n<p>\u00cen cele din urm\u0103, vom folosi interviuri cu pacien\u021bii pentru a explora experien\u021ba acestora, a identifica rezultatele importante ale pacien\u021bilor \u0219i a eviden\u021bia dificult\u0103\u021bile comune cu care se confrunt\u0103 pacien\u021bii trata\u021bi cu aceste medicamente, concentr\u00e2ndu-ne pe explorarea inegalit\u0103\u021bilor \u00een materie de s\u0103n\u0103tate.<\/p>\n<h2>Cine conduce cercetarea?<\/h2>\n<p>Dr. Jennifer Phillips, cercet\u0103tor clinic academic \u00een gastroenterologie.<\/p>\n<h2>Informa\u021bii suplimentare:<\/h2>\n<p>Pentru mai multe informa\u021bii sau pentru a v\u0103 implica \u00een acest proiect, v\u0103 rug\u0103m s\u0103 contacta\u021bi bnssg.research@nhs.net<\/p>\n  <\/div>\r\n  <\/section><\/div><!-- .assembler_text-module.assembler_module.assembler_text-module_1.assembler_module_1..transparent --><\/div><!-- .assembler_module_area.assembler_module_area_1 --><\/div><!-- .assembler_default-group.assembler_module_group.assembler_default-group_1.assembler_module_group_1  -->","protected":false},"excerpt":{"rendered":"<p>Section titled module-1 How can we optimise the management of patients with Inflammatory Bowel Disease? What is the proposed research question? How can we optimise the management of patients with Inflammatory Bowel Disease? Funding BNSSG ICB Research Capability Funding. What is the problem? Inflammatory bowel disease (IBD), Crohn\u2019s Disease (CD) and ulcerative colitis (UC), are [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":32896,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_acf_changed":false,"footnotes":""},"tags":[],"class_list":["post-34651","page","type-page","status-publish","hentry"],"acf":[],"_links":{"self":[{"href":"https:\/\/bnssghealthiertogether.org.uk\/ro\/wp-json\/wp\/v2\/pages\/34651","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/bnssghealthiertogether.org.uk\/ro\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/bnssghealthiertogether.org.uk\/ro\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/bnssghealthiertogether.org.uk\/ro\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/bnssghealthiertogether.org.uk\/ro\/wp-json\/wp\/v2\/comments?post=34651"}],"version-history":[{"count":1,"href":"https:\/\/bnssghealthiertogether.org.uk\/ro\/wp-json\/wp\/v2\/pages\/34651\/revisions"}],"predecessor-version":[{"id":34652,"href":"https:\/\/bnssghealthiertogether.org.uk\/ro\/wp-json\/wp\/v2\/pages\/34651\/revisions\/34652"}],"up":[{"embeddable":true,"href":"https:\/\/bnssghealthiertogether.org.uk\/ro\/wp-json\/wp\/v2\/pages\/32896"}],"wp:attachment":[{"href":"https:\/\/bnssghealthiertogether.org.uk\/ro\/wp-json\/wp\/v2\/media?parent=34651"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/bnssghealthiertogether.org.uk\/ro\/wp-json\/wp\/v2\/tags?post=34651"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}